ESMO 2026 | IMA402-101: IMA402, a PRAME-targeted TCR BiTE, in advanced solid tumours
Han Chong Toh, MD, National Cancer Centre Singapore, Singapore, highlights initial results from the first-in-human Phase I/II IMA402-101 study (NCT05958121) of IMA402, a PRAME-targeted T-cell receptor-based bispecific T-cell engager (BiTE), in heavily pretreated patients with advanced solid tumors. IMA402 showed favorable tolerability, with mainly low-grade cytokine release syndrome and no neurotoxicity. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It was interesting. So that was a German study and that was really a PRAM targeting TCR engager. So what that means is that it’s got an antibody part and then it’s got a T-cell receptor part. So what it does is it latches on to PRAM which is a peptide on the HLA class 1 and only in selected patients. So essentially the idea is to look at its benefit in melanoma patients beyond the first line setting...
It was interesting. So that was a German study and that was really a PRAM targeting TCR engager. So what that means is that it’s got an antibody part and then it’s got a T-cell receptor part. So what it does is it latches on to PRAM which is a peptide on the HLA class 1 and only in selected patients. So essentially the idea is to look at its benefit in melanoma patients beyond the first line setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
